Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Durable hematopoiesis and tolerance after vertebral bone marrow transplant from a deceased lung transplant donor
Paul Szabolcs, Xiaohua Chen, Marian G. Michaels, Memphis Hill, Evelyn Garchar, Zarreen Amin, Heather M. Stanczak, Shawna McIntyre, Aleksandra Petrovic, Dhivyaa Rajasundaram, Ansuman Chattopadhyay, Jonathan E. Spahr, Peter D. Wearden, Geoffrey Kurland
Paul Szabolcs, Xiaohua Chen, Marian G. Michaels, Memphis Hill, Evelyn Garchar, Zarreen Amin, Heather M. Stanczak, Shawna McIntyre, Aleksandra Petrovic, Dhivyaa Rajasundaram, Ansuman Chattopadhyay, Jonathan E. Spahr, Peter D. Wearden, Geoffrey Kurland
View: Text | PDF
Research Article Clinical Research Hematology Immunology

Durable hematopoiesis and tolerance after vertebral bone marrow transplant from a deceased lung transplant donor

  • Text
  • PDF
Abstract

We hypothesized that bone marrow transplantation (BMT) using marrow extracted from the vertebral bodies (VBs) of an unrelated deceased lung transplant donor would be able to establish persistent hematopoiesis and generate immunity and tolerance. A teenager with severe combined immunodeficiency with lung failure due to recurrent pneumonias underwent lung transplantation in 2016 from a 1/8 HLA allele–matched unrelated donor, followed by BMT 4 months later using T cell/B cell–depleted, cryopreserved VB marrow. Rapid engraftment was followed by accelerating immune competence at 6 months, with independence from immunosuppression by 16 months. Donor T cell (>95%) and myeloid chimerism (7%–10%) has persisted for over 9 years. At 2 years after BMT, circulating T cells were hyporesponsive to host dendritic cells in vitro. T cell receptor clonotyping revealed the disappearance of host-reactive clones, and T cell RNA sequencing exhibited downmodulated signaling pathways for cytotoxicity/rejection, paired with upregulated immunomodulatory pathways, suggesting active suppression. In parallel, host monocytes upregulated certain signaling pathways, indicating active interactions between post-thymic donor T cells and host monocytes. In summary, for the first time to our knowledge, durable hematopoietic engraftment, immunity, and tolerance were demonstrable in a recipient of BMT obtained from a VB graft.

Authors

Paul Szabolcs, Xiaohua Chen, Marian G. Michaels, Memphis Hill, Evelyn Garchar, Zarreen Amin, Heather M. Stanczak, Shawna McIntyre, Aleksandra Petrovic, Dhivyaa Rajasundaram, Ansuman Chattopadhyay, Jonathan E. Spahr, Peter D. Wearden, Geoffrey Kurland

×

Figure 2

Longitudinal monitoring of donor cell chimerism and pulmonary function tests.

Options: View larger image (or click on image) Download as PowerPoint
Longitudinal monitoring of donor cell chimerism and pulmonary function t...
(A) Pulmonary function test results prior to BOLT and over time thereafter. The y axis depicts percent predicted values. Arrows indicate the timing of BOLT (September 2015) and BMT (January 2016). (B) STR chimerism for whole peripheral blood (PB) leukocytes. (C) Chimerism of CD3+ T cells. (D) Chimerism of myeloid cells, including CD33+ cells tested by STR assay and monocytes tested by flow cytometry (FC). (E) Chimerism of CD19+ B cells. (F) Chimerism of CD56+ NK cells. The y axes depict percentage donor contribution at various time points after BMT, as indicated on the x axes. Black triangles represent donor chimerism measured by FC on PB leukocytes, red squares indicate data tested using FC on bronchoalveolar lavage (BAL), and blue circles display chimerism data tested by STR assay on purified CD3+ and CD33+ cells from PB. Green circles indicate STR assay on whole PB leukocytes. The antibodies used for FC chimerism include CD45-PerCP, CD3-BV421, CD19-BV510, and CD56-PE-Cy7 (BioLegend), along with donor-specific HLA-B12-FITC antibody and host-specific HLA-A9 biotin-conjugated antibody (both from One Lambda Solutions at Thermo Fisher Scientific).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts